Pub. Date : 2012 Dec
PMID : 23082898
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | OBJECTIVES: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |
2 | CONCLUSIONS: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. | Tacrolimus | BH3 interacting domain death agonist | Homo sapiens |